Literature DB >> 2843574

Role of central alpha-1 adrenoceptors in canine narcolepsy.

E Mignot1, C Guilleminault, S Bowersox, A Rappaport, W C Dement.   

Abstract

The role of central alpha-1 adrenergic receptors in cataplexy was investigated in genetically narcoleptic Doberman pinschers. Treatment of narcoleptic dogs with 25-600 micrograms/kg prazosin, a selective alpha-1 adrenergic receptor blocker, exacerbated cataplexy, whereas treatment with the alpha-1 agonist, methoxamine, ameliorated it. Subsequent studies showed that the beneficial effects of classical treatments of human narcolepsy (amphetamines and tricyclic antidepressants) are antagonized by prazosin, suggesting that these drugs are active through an indirect alpha-1 stimulation (via an increase of norepinephrine in the synaptic cleft). Other studies confirmed that the observed effects were not due to peripheral alpha-1 cardiovascular involvement. Atropine, a central anticholinergic agent, but not methylatropine, a peripheral one, completely suppressed the prazosin effect, which suggests that adrenergic and cholinergic systems act sequentially and not independently to generate cataplexy. Little is known about the physiological role of central alpha-1 adrenoceptors. This series of experiments implicates these receptors in narcolepsy-cataplexy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843574      PMCID: PMC303598          DOI: 10.1172/JCI113694

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Apha-adrenergic receptor blockade increases human REM sleep.

Authors:  I Oswald; V R Thacore; K Adam; V Brezinová
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

2.  Sleep suppression induced by intravenous and intraventricular infusions of methoxamine in the dog.

Authors:  W B Pickworth; L G Sharpe; M Nozaki; W R Martin
Journal:  Exp Neurol       Date:  1977-12       Impact factor: 5.330

Review 3.  Biogenic amines and the states of sleep.

Authors:  M Jouvet
Journal:  Science       Date:  1969-01-03       Impact factor: 47.728

4.  Minireview. Catecholamines and the sleep-wake cycle. II. REM sleep.

Authors:  J M Monti
Journal:  Life Sci       Date:  1983-03-28       Impact factor: 5.037

Review 5.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

6.  Noradrenergic alpha 1 and alpha 2 receptors: light microscopic autoradiographic localization.

Authors:  W S Young; M J Kuhar
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

7.  Effects of 6-hydroxydopamine on sleep in the rat.

Authors:  E Hartmann; R Chung; P R Draskoczy; J J Schildkraut
Journal:  Nature       Date:  1971-10-08       Impact factor: 49.962

8.  Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors.

Authors:  P Greengrass; R Bremner
Journal:  Eur J Pharmacol       Date:  1979-05-01       Impact factor: 4.432

9.  Noradrenergic action of amphetamine following degeneration of descending monoaminergic fibers in the spinal cord.

Authors:  M Nozaki; J A Bell; W R Martin
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

10.  The effect of alpha and beta adrenergic receptor blockers on sleep in the rat.

Authors:  E Hartmann; G Zwilling
Journal:  Pharmacol Biochem Behav       Date:  1976-08       Impact factor: 3.533

View more
  9 in total

Review 1.  Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up.

Authors:  C Guilleminault; R Pelayo
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission.

Authors:  C Sebban; X Q Zhang; B Tesolin-Decros; M J Millan; M Spedding
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 4.  Good night and good luck: norepinephrine in sleep pharmacology.

Authors:  Heather A Mitchell; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2009-10-13       Impact factor: 5.858

5.  Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy.

Authors:  S Nishino; E Mignot; B Fruhstorfer; W C Dement; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

6.  Animal models of narcolepsy.

Authors:  Lichao Chen; Ritchie E Brown; James T McKenna; Robert W McCarley
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-08       Impact factor: 4.388

7.  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.

Authors:  E Mignot; A Renaud; S Nishino; J Arrigoni; C Guilleminault; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Cataplexy-related neurons in the amygdala of the narcoleptic dog.

Authors:  S Gulyani; M-F Wu; R Nienhuis; J John; J M Siegel
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

9.  Sleep, Narcolepsy, and Sodium Oxybate.

Authors:  Mortimer Mamelak
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.